SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Keymed Biosciences Doses First Patient In Phase I Trial Of CM350

reuters.com · 06/10/2022 07:22
BRIEF-Keymed Biosciences Doses First Patient In Phase I Trial Of CM350

- Keymed Biosciences Inc 2162.HK:

  • KEYMED BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN PHASE I TRIAL OF BISPECIFIC ANTIBODY CM350

Source text for Eikon: ID:nPn1NSqjWa

Further company coverage: 2162.HK


((Reuters.Briefs@thomsonreuters.com;))